Reversible hyposmia caused by intracranial tumour

Ishimaru, Tadashi; Miwa, Takaki; Nomura, Motohiro; Iwato, Masayuki; Furukawa, Mituru

doi:10.1017/s0022215100145104

Cited by 8 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Welge-Leussen et al suggest that all patients with lateralised dysosmia should undergo radiological evaluation, after noting that 50 per cent of patients with olfactory meningiomas had unilateral dysosmia on formal testing. Recovery of olfaction following intracranial surgery is not well documented, although Ishimaru et al report improved olfactory function in a patient following decompression of a right frontal lobe meningioma 24 …”

Section: Literature Reviewmentioning

confidence: 99%

Diagnosis and management of olfactory disorders: survey of UK-based consultants and literature review

2007

View full text Add to dashboard Cite

Management of olfactory pathology varies across the United Kingdom. The literature suggests that chemosensory testing is optimal and that both forced-choice and threshold testing should be applied if objective evaluation is required. Imaging can be of value but the appropriate technique should be used. Olfactory function can recover following head injury, viral infection and chronic sinonasal disease, although varying degrees of dysfunction are likely to persist. There is a role for the use of corticosteroids, particularly when administered systemically. More research is needed to establish the appropriate dose and length of treatment.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Diagnosis and management of olfactory disorders: survey of UK-based consultants and literature review

2007

View full text Add to dashboard Cite

show abstract

“…Ishimaru et al. described a case report of reversible hyposmia, after removal of a right frontal lobe lung cancer metastasis which was causing slight compression and swelling of the olfactory area in the brain ( 26 ).…”

Section: Resultsmentioning

confidence: 99%

Managing Severe Dysgeusia and Dysosmia in Lung Cancer Patients: A Systematic Scoping Review

et al. 2021

View full text Add to dashboard Cite

IntroductionLung cancer (LC) is highly prevalent worldwide, with elevated mortality. In this population, taste and smell alterations (TSAs) are frequent but overlooked symptoms. The absence of effective therapeutic strategies and evidence-based guidelines constrain TSAs’ early recognition, prevention and treatment (Tx), promoting cancer-related malnutrition and jeopardizing survival outcomes and quality of life.ObjectivesTo systematically review the literature on TSAs in LC patients, understand the physiopathology, identify potential preventive and Tx strategies and to further encourage research in this area.MethodsLiterature search on English language articles indexed to PubMed, CINALH, SCOPUS and Web of Science using MeSH terms “Lung neoplasms”,”Dysgeusia”, “Olfaction Disorders”, “Carcinoma, Small Cell”,”Carcinoma, Non- Small-Cell Lung “Adenocarcinoma of Lung”,”Carcinoma, Large Cell”, and non-MeSH terms “Parageusia”, “Altered Taste”, “Smell Disorder”, “Paraosmia”, “Dysosmia”,”Lung Cancer” and “Oat Cell Carcinoma”.ResultsThirty-four articles were reviewed. TSAs may follow the diagnosis of LC or develop during cancer Tx. The estimated prevalence of self-reported dysgeusia is 35-38% in treatment-naïve LC patients, and 35-69% in those undergoing Tx, based on studies involving LC patients only.One prospective pilot trial and 1 RCT demonstrated a clinically significant benefit in combining flavor enhancement, smell and taste training and individualized nutritional counselling; a systematic review, 1 RCT and 1 retrospective study favored using intravenous or oral zinc-based solutions (150mg 2-3 times a day) for the prevention and Tx of chemotherapy (CT) and radiotherapy (RT) -induced mucositis and subsequent dysgeusia.ConclusionsThis is the first review on dysgeusia and dysosmia in LC patients to our knowledge. We propose combining taste and smell training, personalized dietary counselling and flavor enhancement with oral zinc-based solutions (150mg, 2-3 times a day) during CT and/or RT in this population, in order to prevent and help ameliorate Tx-induced dysgeusia and mucositis. However due to study heterogeneity, the results should be interpreted with caution. Developing standardized TSA measurement tools and performing prospective randomized controlled trials to evaluate their effect are warranted.

show abstract

“…However, brain metastases have caused reversible anosmia from direct olfactory system involvement. 85 Olfactory sensations during the course of brain irradiation occur when high-energy photons produce ozone that stimulates the olfactory mucosa. The patient experiences an unpleasant odor.…”

Section: Gastrointestinal Problemsmentioning

confidence: 99%

Brain Metastases

Kamar

Posner

2010

Semin Neurol

View full text Add to dashboard Cite

Approximately 10% of patients with cancer develop brain metastases. Some evidence indicates that as techniques for treating systemic tumors improve, the incidence of brain metastases, sequestered as they are behind the blood-brain barrier, is increasing. Although usually appearing late in the course of the disease, a brain metastasis may cause the initial symptoms, before the primary cancer has been identified. The diagnostic and therapeutic approach depends on the number and location of brain lesions and the stage of the cancer. Patients with brain metastases are rarely cured. However, appropriate treatment can improve both the quality and duration of the patient's life. Treatment must be directed not only at the brain metastasis (definitive care), but also at a multitude of other symptoms that plague patients with brain metastases (supportive care). Judicious selection of pharmacologic agents and nonpharmacologic techniques can effectively treat many serious symptoms in patients with brain metastases, but injudicious selection of pharmacologic agents may have side effects and make the patient's quality of life worse. The authors review some aspects of both definitive and supportive care with particular attention to the side effects of some commonly used pharmacologic agents.

show abstract

Reversible hyposmia caused by intracranial tumour

Cited by 8 publications

References 6 publications

Diagnosis and management of olfactory disorders: survey of UK-based consultants and literature review

Diagnosis and management of olfactory disorders: survey of UK-based consultants and literature review

Managing Severe Dysgeusia and Dysosmia in Lung Cancer Patients: A Systematic Scoping Review

Brain Metastases

Contact Info

Product

Resources

About